About the Company
DSV A/S is a Danish transport and logistics company offering global transport services by road, air, sea and train. Since its foundation in 1976 by nine independent Danish hauliers, the company has achieved rapid expansion and international presence, predominantly through a series of strategic competitor acquisitions, some of the most important ones being Samson Transport (1997), DFDS Dan Transport Group (2000), J.H.Bachmann (2004), Frans Maas (2006), ABX LOGISTICS (2008), UTi Worldwide, Inc. (2016), Panalpina Welttransport (Holding) AG (2019) and Agility Global Integrated Logistics (GIL) (2021). With headquarters in Hedehusene (near Copenhagen), Denmark, and offices in more than 80 countries, DSV employs more than 75,000 people and collaborates with partners and agents globally. The company is listed on NASDAQ OMX Copenhagen (Copenhagen Stock Exchange) and included in the OMXC25 index as one of the 25 most traded stocks. The company is structured in three divisions, Road, Air & Sea, and Solutions. Its main activities lie within road transport (trucking) networks in Europe, North America and South Africa, global air and sea freight forwarding business, and contract logistics across the globe. As part of an asset-light financial strategy to maintain fixed costs at a minimum and be able to quickly respond to market fluctuations, the group does not own any ships or aeroplanes and only a relatively small fleet of trucks and trailers. Jens Lund became CEO in February 2024. In 2022, the company reported a net revenue of DKK 235,665 million.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CHFS News
CHF Solutions, Inc. Acquires Impedance Technology from Vasamed, Inc.
CHF Solutions, Inc. (Nasdaq:CHFS) announced today it has acquired the AcQtrac™ System technology from Vasamed, Inc. The AcQtrac System is a patented, non-invasive device designed to measure ...
Intravenous Therapy for Hypertensive Emergencies, Part 2
Dr. Peacock has served on the scientific advisory boards or speakers' bureaus of or received research grants from Abbott, BAS, Beckman-Coulter, Biosite, Brahms, CHF Solutions, Heartscape ...
Geberit Q1 Results Down; To Buy Back Up To CHF 300 Mln Shares
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
BrioHealth Solutions Secures Nod from FDA to Begin the INNOVATE Trial Featuring the BrioVAD™ System for Advanced Heart Failure
BURLINGTON, Mass., May 1, 2024 /PRNewswire/ -- BrioHealth Solutions, Inc., a medical technology company focused on developing innovative advanced heart failure solutions, today announced it has ...
Balancing Diuretic Therapy in Heart Failure: Loop Diuretics, Thiazides, and Aldosterone Antagonists
Although diuretics do not directly treat the pathologic changes that occur with heart failure, they are the ... despite diuretic therapy. Solutions to this problem include eating a low-sodium ...
BridgeBio Pharma spins out cancer-focused unit with three drugs, $200 million
With $200 million and three drugs in or near clinical trials, a spinout of BridgeBio Pharma Inc. aims to flip the switch on a ...
BKW Secures CHF 1 Billion Credit Facility, Preemptively Refinances Existing Loans
BKW, a Swiss energy company, has announced the agreement of a new unsecured, committed revolving credit facility amounting to ...
Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing
BERN, Switzerland and BOSTON, May 02, 2024 - Ikerian AG and its subsidiary, RetinAI U.S. Inc., a leading developer of ...
Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing
BERN, Switzerland and BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Ikerian AG and its subsidiary, RetinAI U.S. Inc., a leading developer ... close of its USD 6.18M (CHF 5.65M) Series A Extension ...
Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing
Total of USD 11.66M (CHF 10.66M) raised across Seed ... Ikerian AG and its subsidiary, RetinAI U.S. Inc., a leading developer of software solutions for medical image and data management, and ...
Loading the latest forecasts...